A Phase 2a, Multicenter, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Resmetirom in Pediatric Subjects Ages 6-17 Years with MASH with Fibrosis Stage F1-F3
Clinical Trial Grant
Administered By
Radiology, Abdominal Imaging
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
June 20, 2026
End Date
March 31, 2029
Administered By
Radiology, Abdominal Imaging
Awarded By
Madrigal Pharmaceuticals, Inc.
Start Date
June 20, 2026
End Date
March 31, 2029